SOPHiA GENETICS announced a new collaboration with Jessa Ziekenhuis in Hasselt, Belgium, aimed at bringing cutting-edge genomic testing and oncology research to cancer patients across the country. Jessa Ziekenhuis, one of Belgium's largest healthcare institutions, processes over 3,000 oncology DNA and RNA samples annually.
Through this partnership, Jessa Ziekenhuis will adopt the SOPHiA DDM™ platform across its pathology operations to unify its next-generation sequencing (NGS) workflows. This standardization, covering universal library preparation, automated protocols, and a fully integrated workflow, is expected to ensure efficiency, harmonization, and compliance with national guidelines.
The hospital plans to implement six SOPHiA GENETICS applications tailored to its needs in solid tumors, hematologic malignancies, and liquid biopsy analysis. This integrated approach is projected to cut hands-on time by 30-50%, reduce overall costs by up to 25%, and accelerate testing turnaround times, while also enabling Jessa Ziekenhuis to share a NovaSeq sequencer with AZ Delta via the SOPHiA DDM™ Dispatch feature.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.